EDAP - CONSENSUS CO - EDAP TMS S.A.

EDAP TMS S.A. (EDAP) minimizes physician errors by implementing robotic ultrasound ablation systems for tumor treatment. The company is actively scaling non-invasive prostate cancer therapies, which are critical for the medical landscape of 2026. Serving as a valuation tool, this chart of the stock price on GURU.Markets, where the consensus stands at , confirms the business's resilience to crises due to the defensive qualities of high-tech equipment and stable demand for treatment.

This indicator represents a weighted average fair value assessment of the asset, aggregating forecasts from leading investment houses to determine market potential. Geopolitical fragmentation and export barriers in the ultrasound systems sector directly impact the consensus target price of the stock, where any downward trend signals capital risks due to declining service revenue for EDAP TMS S.A.